News

A University of British Columbia bioengineer has developed a potential strategy for endowing platelets with extra powers so they can rise to the occasion and continue coagulation.

In a world first, scientists have revealed how a population of 'bad' antibodies in the immune system - which are usually 'silenced' because they can harm the body - can provide crucial protection against invading microbes.

First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.

A new type of cancer vaccine has yielded promising results in an initial clinical trial. The personalized vaccine is made from patients’ own immune cells, which are exposed in the laboratory to the contents of the patients’ tumor cells, and then injected into the patients to initiate a wider immune response.

A vaccine may successfully turn off peanut allergy in mice, a new study shows. Just three monthly doses of a nasal vaccine protected the mice from allergic reactions upon exposure to peanut, according to new research.

The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.

Adding the monoclonal antibody drug trastuzumab - already used to treat certain breast cancers - to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small Phase II trial of the regimen, testing its safety and value.

Christoph Rader, PhD, associate professor at the Florida campus of The Scripps Research Institute, has been awarded a $2.875 million, five-year grant from the National Cancer Institute to develop unique antibody-drug conjugates engineered to eradicate one of the most common forms of leukemia, chronic lymphocytic leukemia (CLL).

Using human brain cells, scientists at the Gladstone Institutes discovered the cause of—and a potential solution for—the primary genetic risk factor for Alzheimer’s disease, a gene called apoE4.

The human piece of a malaria infection puzzle has been revealed for the first time, solving a long-standing mystery. A protein displayed on the surface of malaria parasites called "TRAP" is a high-priority vaccine target, but how it interacts with human host cells has remained a puzzle.